Cancers最新文献

{"title":"A Pilot Head-to-Head Comparison of Two Bisulfite Conversion Kits for NGS-Based DNA Methylation Analysis of Liquid Biopsy Samples from Colorectal Cancer.","authors":"Omayma Mazouji, Abdelhak Ouhajjou, Roberto Incitti, Chakib Nejjari, Menter David, Morris Van Karlyle, Raghav Kanwal Pratap Singh, Scott Kopetz, Hicham Mansour","doi":"10.3390/cancers18193148","DOIUrl":"10.3390/cancers18193148","url":null,"abstract":"<p><p>Given the important role of early detection in improving cancer outcomes, epigenetic alterations, particularly DNA methylation, have emerged as powerful biomarkers for cancer screening and diagnosis. However, methylation profiling of cfDNA (circulating free DNA) presents particular technical challenges because cfDNA is typically present at very low concentrations and is highly fragmented. Bisulfite conversion, although essential for distinguishing methylated from unmethylated cytosines, can further compromise DNA integrity through chemical-induced loss of DNA during purification steps. Inadequate conversion or excessive DNA loss may consequently reduce library complexity, increase DNA duplication rates, and negatively affect mapping efficiency and downstream sequencing quality. Therefore, optimizing bisulfite conversion is particularly important for reliable methylation profiling of low-input cfDNA. The effectiveness of these diagnostic approaches relies on the accurate detection of DNA methylation patterns, which is fundamentally dependent on the efficiency of bisulfite conversion of genomic DNA. This pilot study aims to compare the performance of two widely used bisulfite conversion kits, namely the EpiTect Bisulfite (EpiTect) Kit (Qiagen, Hilden, Germany) and the EZ DNA Methylation (Zymo) Kit (Zymo Research, Irvine, CA, USA), in the context of plasma-derived cfDNA methylation profiling using five samples, including two plasma samples from metastatic colorectal cancer (mCRC) patients collected at the Department of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, in Houston, TX, USA, and two plasma samples from healthy donors (controls) purchased from Innovative Research (Novi, MI, USA), along with one control DNA sample (Corriel NA12878-N88). Our objective was to evaluate and compare their conversion efficiency, mapping efficiency (percentage of mapped and unmapped reads), duplication rate, and distribution of methylated cytosines in CpG, CHG, and CHH contexts. Our results indicate that samples processed using the Zymo kit consistently outperformed those treated with the EpiTect kit across multiple performance metrics. The Zymo-treated samples yielded a higher concentration of cfDNA following bisulfite conversion (125.34 nM vs. 45.60 nM in samples processed with the Epitect kit). Additionally, the Zymo kit achieved a higher average bisulfite conversion efficiency (99.3% vs. 95.7%), as well as a significantly higher average mapping rate (94.86% vs. 72.4%), with fewer unmapped reads and lower duplication rates. Head-to-head comparison of Bismark methylation calls across the same reference regions showed high concordance between the two protocols. The SEPT9 region was strongly hypermethylated with both protocols (100% with EpiTect and approximately 94% with Zymo), whereas the BMP3 region was predominantly unmethylated (approximately 4% with EpiTect and 7% with Zymo). These findings suggest that the Zymo kit dem","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Sulfation: Integrated Immunohistochemical, Genomic, and Proteomic Profiling Identifies PAPSS1 as a Potential Regulator of Breast Cancer Progression.","authors":"Rabab Ahmed Ahmed Mohammed, Amina Ismaeel, Safa Alshaikh, Aalaa Mubarak, Sajedah Sabt, Samvel Selvam","doi":"10.3390/cancers18193143","DOIUrl":"10.3390/cancers18193143","url":null,"abstract":"<p><p><b>Background:</b> PAPSS1 (3'-Phosphoadenosine 5'-Phosphosulfate Synthase 1) plays a central role in the sulfation process that regulates estrogen activity; however, its pattern of expression and association with clinicopathological features in breast carcinoma (BC) are not fully examined. <b>Methods:</b> A total of 150 BC specimens with clinicopathological and 10-year follow-up data were analyzed. PAPSS1 protein expression was assessed using immunohistochemistry (IHC) and correlated with clinicopathological parameters and patient outcome. Transcriptomic and promotor methylation analyses were performed using TCGA-BRCA through UALCAN. Proteomic data was evaluated using the CPTAC dataset, and the gene interaction network was analyzed using STRING. <b>Results:</b> IHC demonstrated significantly higher PAPSS1 expression in invasive carcinomas compared with non-invasive carcinoma and with normal mammary acini (<i>p</i> < 0.0001). High expression was associated with the presence of vascular invasion (VI) (<i>p</i> = 0.003), LN metastasis (<i>p</i> = 0.008), and higher PAPSS1 expression in tumor capillaries (<i>p</i> < 0.001). CPTAC analyses confirmed significantly elevated PAPSS1 in tumors versus normal tissues (<i>p</i> < 0.0001), particularly in stage II and III tumors, triple-negative BC, and basal stromal-related molecular subtypes. The transcriptomic data showed different expression patterns according to tissue type; it is higher in GIT tumors. The opposite was found in lung and pancreatic carcinoma. In BC, transcriptional expression was not different between normal and tumors; it was lower in higher nodal stages and highest in medullary carcinoma and in TP53-mutant tumors. <b>Conclusions:</b> PAPSS1 is overexpressed in BC and is associated with VI, LN metastasis, and tumor progression, suggesting a potential role in BC aggressiveness. Further studies are recommended to explore its mechanistic role.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological Subtype Provides Limited Prognostic Information in Grade 1 Invasive Breast Carcinoma: A Retrospective Cohort Study.","authors":"Eleonore Locher, Lara Benning, Zsuzsanna Varga","doi":"10.3390/cancers18193154","DOIUrl":"10.3390/cancers18193154","url":null,"abstract":"<p><p><b>Background:</b> Histological grade is one of the strongest prognostic factors in invasive breast cancer. However, it remains unclear whether histological subtype provides additional prognostic information in well-differentiated (grade 1; G1) invasive breast carcinomas. This study investigated the distribution of histological subtypes in G1 breast cancers and evaluated their impact on overall survival. <b>Methods:</b> In this retrospective single-centre study, all patients diagnosed with G1 invasive breast carcinoma in a single institution between 2005 and 2014 were identified. Histopathological and clinical data were retrieved from institutional pathology and clinical databases. Tumours were classified as no special type (NST), pure special type, or mixed subtype. Overall survival was analysed using Kaplan-Meier estimates and compared with the log-rank test. Associations between histological subtype and mortality were evaluated using the chi-squared test. <b>Results:</b> Of 429 initially identified patients, 364 fulfilled the inclusion criteria. NST represented the predominant subtype (67.3%), whereas pure special types and mixed subtypes accounted for 15.1% and 15.7% of cases, respectively. Tubular carcinoma was the most frequent pure special subtype, followed by mucinous, cribriform, papillary, lobular and adenoid cystic carcinoma. After exclusion of patients with simultaneous higher-grade contralateral carcinomas, 348 patients were included in survival analyses. The overall 5- and 10-year survival rates were 94.7% and 85.4%, respectively. Pure special types showed the highest survival rates numerically, whereas mixed subtypes had the lowest. However, overall survival did not differ significantly between NST, pure special types and mixed subtypes (log-rank <i>p</i> = 0.39). Likewise, no significant survival differences were observed among individual pure special subtypes (<i>p</i> = 0.20), and no significant association between histological subtype and mortality was identified (χ²<i>p</i> = 0.064). <b>Conclusions:</b> Within this cohort of G1 invasive breast carcinomas, no statistically significant association between histological subtype and overall survival was identified. However, clinically relevant differences cannot be excluded given the heterogeneity of the cohort and the small number of events. Larger studies incorporating multivariable analyses and breast cancer-specific outcomes are needed to further clarify the prognostic relevance of histological subtype in G1 invasive breast cancer.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Cell and Multi-Omics Profiling of the Multiple Myeloma Immune Niche: From Bone Marrow Architecture and Metabolic Reprogramming to Immunotherapy Response.","authors":"Katia Beider, Olga Ostrovsky, Arnon Nagler","doi":"10.3390/cancers18193158","DOIUrl":"10.3390/cancers18193158","url":null,"abstract":"<p><p>Multiple myeloma (MM) is increasingly understood as a spatially organized and dynamically evolving disease, in which malignant plasma-cell behavior is shaped by local immune, stromal, vascular, and metabolic contexts. Single-cell, spatial, and multi-omic technologies have resolved tumor-cell heterogeneity, bone marrow niche remodeling, immune dysfunction, and therapy-induced selection at unprecedented resolution, yet an integrated synthesis linking marrow architecture, extramedullary dissemination, circulating tumor cells, metabolic reprogramming, chimeric antigen receptor T (CAR-T) cell and T-cell-redirecting immunotherapy, and stem-cell transplantation remains lacking. Here, we review how malignant subclones occupy distinct marrow regions, focal lesions, and extramedullary sites with different transcriptional, antigenic, immune-interactive, and metabolic states. We discuss how spatial transcriptomics and multiplexed imaging reveal immune exclusion, stromal support, oxidative and glycolytic niches, and region-specific antigen heterogeneity. We further examine how circulating tumor cells serve as liquid readouts of tumor burden, high-risk genomics, and clonal evolution. Emphasis is placed on CAR T-cell and T-cell engager therapies, where response and resistance depend on antigen retention, effector-cell fitness, clonal T-cell expansion, myeloid suppression, and spatial accessibility. Finally, we consider autologous hematopoietic stem-cell transplantation as a clinical model of cytoreduction, lymphodepletion, and incomplete immune reconstitution. We propose that MM progression and relapse should be interpreted through an integrated spatial-temporal framework, in which therapeutic outcome reflects the interaction between malignant plasma-cell plasticity, immune competence, stromal persistence, metabolic adaptation, and residual disease localization.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Novel Organic Arsenical PZ2 Exhibits Potent Anti-T-ALL Activity via ROS-Dependent Apoptosis and <i>GABARAPL1</i>-Induced Autophagic Cell Death.","authors":"Xian Zhang, Zhuping Chen, Yujiao Liu, Dongdong Zhang","doi":"10.3390/cancers18193150","DOIUrl":"10.3390/cancers18193150","url":null,"abstract":"<p><p><b>Objective:</b> T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematological malignancy with poor overall prognosis. This study systematically evaluates the anti-leukemic therapeutic potential and underlying redox-driven mechanisms of PZ2, a novel organic arsenic compound, in T-ALL. <b>Methods:</b> The cytotoxicity of PZ2 against T-ALL cell lines and normal cells was assessed to determine its therapeutic window. RNA-seq was utilized to map transcriptomic alterations. Intracellular redox homeostasis, mitochondrial membrane potential (MMP), cell cycle, and apoptosis were evaluated using flow cytometry and fluorescence microscopy. Ultrastructural changes and key protein expressions were analyzed via TEM, RT-qPCR, and immunoblotting. In vivo efficacy was validated using a T-ALL cell-line-derived xenograft (CDX) mouse model. <b>Results:</b> PZ2 exhibited superior cytotoxicity and an improved safety profile compared to inorganic arsenic trioxide (ATO). Transcriptomic data indicated strong enrichment in apoptosis and autophagy-lysosome pathways. PZ2 induced profound mitochondrial oxidative stress, leading to ROS accumulation, MMP loss, and subsequent activation of caspase-dependent apoptosis-effects that were completely rescued by ROS scavengers. Furthermore, PZ2 triggered G2/M phase arrest and activated autophagic flux (upregulated <i>GABARAPL1</i> and LC3-II, degraded p62). Notably, pharmacological inhibition of autophagy rescued PZ2-induced apoptosis, revealing a pro-death autophagic mechanism. In vivo, PZ2 significantly suppressed tumor growth and prolonged survival without overt systemic toxicity. <b>Conclusions:</b> PZ2 exhibits potent anti-T-ALL activity that may involve a dual mechanism: ROS-dependent mitochondrial apoptosis and pro-death autophagy potentially associated with <i>GABARAPL1</i>. This novel organic arsenical may represent a promising and potentially safer alternative for leukemia therapy, and these findings suggest a potential interplay between oxidative stress and autophagic cell death.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Cancer Incidence in North-East Spain, 2002-2021: A Population-Based Study.","authors":"Maria Ayala-Conte, Neus Basté, Jan Trallero, Arantza Sanvisens, Montse Puigdemont, Anna Vidal, Aina Romaguera, Wali Guan, Mercè Fernández-Balsells, Rafael Marcos-Gragera, Jordi Rubió-Casadevall, Josefina Biarnés","doi":"10.3390/cancers18193146","DOIUrl":"10.3390/cancers18193146","url":null,"abstract":"<p><p><b>Background/Objectives:</b> The incidence of thyroid cancer (TC) has increased worldwide over recent decades, particularly for well-differentiated histological subtypes, a trend largely attributed to overdiagnosis. Given potential geographical differences, this study analyzed TC incidence and temporal trends in the province of Girona, Spain, between 2002 and 2021. <b>Methods:</b> We conducted a cross-sectional study using data from the Girona Cancer Registry. Crude incidence rates (CRs), age-standardized incidence rates using the 2013 European (ASRe) and the 1960 World (ASRw) standard populations were calculated per 100,000 person-years. Temporal trends were assessed via the annual percentage change (APC) using generalized linear models. <b>Results:</b> A total of 998 incident TC cases were identified. Most patients were women (78.0%), with a median age at diagnosis of 48 years. Papillary TC was the predominant histological subtype (81.7%), and 70.6% of cases were diagnosed at Stage I. The overall ASRe was 6.8 and ASRw was 5.5, with incidence rates 3-4 times higher in women than in men. Overall, TC incidence increased significantly (APC: 2.7%), driven by increases in the 35-44 and ≥55 age groups, papillary histology, and early-stage disease (Stages I-II). <b>Conclusions:</b> The rise in TC incidence in Girona over the last two decades has been largely driven by Stage I papillary tumors, in both sexes, supporting a potentially substantial contribution of overdiagnosis. However, the concurrent increase in Stage II disease warrants continued surveillance, as it may reflect additional risk factors.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Utility of Computed Tomography of the Chest at the Time of Induction Chemotherapy in Patients with Acute Leukemia.","authors":"Maro Ohanian, Fieke W Hoff, Vikas Kundra, Dimitrios P Kontoyiannis, Graciela N Nogueras-Gonzalez, Javier Adachi, Dawid Schellingerhout, Samuel Shelburne, Sherry Pierce, Saadia A Faiz, Yesid Alvarado, Tapan Kadia, Koji Sasaki","doi":"10.3390/cancers18193155","DOIUrl":"10.3390/cancers18193155","url":null,"abstract":"<p><p><b>Background</b>: Compared to chest X-ray, computed tomography (CT) imaging of the chest is more sensitive and specific for identifying pulmonary abnormalities. However, patients with acute leukemia routinely undergo chest X-ray before beginning chemotherapy, and the benefit of obtaining baseline chest CT remains unclear. <b>Methods</b>: In this retrospective study, 50 patients with newly diagnosed acute leukemia who underwent chest X-ray and chest CT without contrast before beginning induction chemotherapy were included. CT imaging reports were independently evaluated by two hematologist-oncologists for infection concern and actionability, and these assessments were compared to the actions taken by the treating physicians. <b>Results</b>: Regardless of the presence of chest X-ray abnormalities, chest CT identified abnormalities in 94% of patients (47/50), a significantly higher detection rate than that for chest X-ray, which demonstrated abnormalities in only 66% of patients (33/50) (<i>p</i> < 0.001). Of the 17 patients with normal chest X-ray findings, 14 (82%) had abnormal chest CT findings. Of these 14 patients, 10 had actionable abnormalities, and four had non-clinically significant findings. All 33 patients with abnormal chest X-ray findings also had abnormal chest CT findings, and three patients with normal chest X-ray findings also had normal chest CT findings. Of the 30 patients with normal or minimal chest X-ray findings compared to chest CT findings, 26 patients (87%) had chest CT findings that were actionable, prompting more aggressive care and/or closer monitoring. On multivariate analysis, patients with both abnormal chest X-ray and chest CT findings had worse overall survival than patients without both abnormal chest X-ray and chest CT findings (<i>p</i> = 0.005). <b>Conclusions</b>: These findings highlight a diagnostic gap, potentially supporting prospective studies on routine chest CT imaging for patients with newly diagnosed acute leukemia.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Multi-Phase-Fused Photon-Counting CT for Pre-TACE Feeding Artery Mapping and DSA Procedural Road-Mapping in Hepatocellular Carcinoma.","authors":"Hao Chen, Hao Deng, Xin Wei, Xi Liu, Weijuan Chen","doi":"10.3390/cancers18193152","DOIUrl":"10.3390/cancers18193152","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Accurate preoperative feeding artery mapping remains challenging for hepatocellular carcinoma (HCC) even with modern CT techniques. This study aimed to optimize dynamic multi-phase photon-counting CT (PCCT) hepatic artery protocols and assess dynamic-fusion PCCT against best single-phase PCCT and energy-integrating-detector dual-energy CT (EID-DECT) for feeding artery detection, vascular-map construction and digital subtraction angiography (DSA) path-planning prior to transarterial chemoembolization (TACE) in HCC. <b>Methods:</b> This prospective single-center study contained workflow-optimization among cirrhotic non-HCC patients and clinical validation in TACE-candidate HCC patients. Two radiologists performed blinded independent reading. The composite reference standard consisted of DSA, selective/superselective angiography, available cone-beam computed tomography (CBCT) and embolization records. Primary endpoint: patient-level paired difference in DSA-verified feeding artery coverage. Secondary endpoints included complete-atlas rate, DSA-path-prediction accuracy, missed-vessel count and extrahepatic-supply detection. A pre-specified comparison between dynamic-fusion PCCT and EID-DECT was performed. <b>Results:</b> Dynamic phase 1-6 fusion was the optimal PCCT scheme, while optimal single-phase varied individually. Dynamic-fusion PCCT achieved superior feeding artery coverage (97.78% ± 8.61% vs. 88.33% ± 15.37%, difference 9.44 pp, 95% CI 1.82-17.06, <i>p</i> = 0.016), complete-atlas rate (93.3% vs. 53.3%, <i>p</i> = 0.039) and path-prediction accuracy (96.67% ± 11.18% vs. 80.00% ± 24.49%), with fewer missed culprit vessels. Two extrahepatic feeders were only detected by dynamic-fusion PCCT. Compared with EID-DECT, dynamic-fusion PCCT showed favorable atlas-related metrics without statistically significant difference in feeding artery coverage. <b>Conclusions:</b> Dynamic-fusion PCCT outperforms single-phase PCCT in pre-TACE feeding artery mapping and DSA path-prediction and shows potential benefits over EID-DECT. It delivers comprehensive preoperative vascular data and may reduce intraoperative exploratory procedures.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Trends in Six Major Cancers: Implications for Lifestyle-Based Cancer Prevention and Early Detection Across the Life Course.","authors":"Itunu Sokale, Omar Rosales, Hashem El-Serag, Natalia Khalaf, Aaron P Thrift, Victor Adekanmbi, Abiodun Oluyomi","doi":"10.3390/cancers18193149","DOIUrl":"10.3390/cancers18193149","url":null,"abstract":"<p><strong>Background/objectives: </strong>Cancer remains a serious public health challenge in the United States. Six major cancers (female breast, colorectal, liver, lung/bronchus, pancreas, and prostate) account for a substantial proportion of the national cancer burden. Understanding the changes in the incidence of these cancers over time can provide insights for prevention and control. This study examined temporal trends in the cancer incidence according to age at onset and stage at diagnosis.</p><p><strong>Methods: </strong>This population-based study analyzed data from the United States Cancer Statistics database for 2001-2023, including all 50 states and the District of Columbia. Joinpoint regression was used to estimate annual percent changes (APCs) and average annual percent changes (AAPCs), with corresponding 95% confidence intervals (CIs), based on age-adjusted incidence rates per 100,000 people. Of note, incidence rates from 2020 data were excluded from the Joinpoint models because COVID-19 pandemic disruptions affected cancer screening, diagnosis, and reporting.</p><p><strong>Results: </strong>From 2001 to 2023, the incidence of lung and colorectal cancers declined, particularly among older adults (aged ≥50 years) (lung cancer: AAPC -2.09; 95% CI: -2.27, -1.90; colorectal cancer AAPC -2.70; 95% CI: -2.83, -2.56). In contrast, the incidence of colorectal, pancreatic, and breast cancers increased among younger adults (aged <50 years), whereas the incidence of liver and lung cancer declined. Moreover, prostate cancer incidence declined over time despite modest rebound in recent years (AAPC 1.83; 95% CI: 0.53, 3.14). Stage-specific analyses revealed increasing rates of early-stage diagnoses for several cancers, while late-stage cancer incidence increased for pancreatic and colorectal cancers (especially among younger adults).</p><p><strong>Conclusions: </strong>Cancer incidence varied substantially by cancer type, age, and stage at diagnosis. The rising incidence of colorectal, pancreatic, and breast cancers among younger adults underscores the need for continued research into risk factors, early detection, and prevention strategies.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Danese et al. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. <i>Cancers</i> 2026, <i>18</i>, 2481.","authors":"Elisa Danese, Alessandro Esposito, Matteo De Pastena, Fabio Del Ben, Gabriella Lionetto, Alessia Scirpoli, Mariateresa Rizza, Roberto Salvia, Giuseppe Lippi","doi":"10.3390/cancers18193144","DOIUrl":"10.3390/cancers18193144","url":null,"abstract":"<p><p>In the original publication [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"18 19","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}